|
|
|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 12:45
|
Niu Technologies Files Its Annual Report on Form 20-F (GlobeNewswire EN)
|
|
|
BEIJING, April 17, 2026 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission. The annual report on Form 20-F can be accessed on the Company's investor relations website at https://ir.niu.com/....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.01.26 - 03:06
|
MindRank in Phase 3 trial with China′s first AI-assisted new drug, cutting R&D costs by 60% (SCMP)
|
|
|
Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its weight-loss drug, making it China's first artificial intelligence-assisted Category 1 new drug to reach this stage.
MindRank announced last month that it had initiated a Phase 3 clinical trial in China for MDR-001, a small molecule GLP-1 receptor agonists designed with the help of AI. GLP-1 receptor agonists mimic natural hormones to regulate blood sugar and appetite.
According to Niu Zhangming, MindRank's......
|
|
|
|